EU regulator backs Eisai-Biogen Alzheimer’s drug
EU drugs regulator recommends approval of Leqembi for early Alzheimer's, pending European Commission acceptance, for specific patient group.
The European Union’s drugs regulator on Thursday (November 14, 2024) recommended approval of Eisai and Biogen’s Leqembi for some patients with early Alzheim...
Read More
Other Stories in Health
- 7 benefits of eating a rainbow diet
- Study shows toddlers learn better from impossible events
- New model sheds light on APOE4's role in Alzheimer's pathology
- How calcium and magnesium deficiencies impact cognitive health
- Lincoln Memorial University CRNA 2025
- Heard of the 'UTI vaccine'? What you need to know about how it treats recurrent infections
- Shah Rukh Khan reveals feeling breathless after quitting smoking, know why this happens
- La Roche University CRNA 2025
- La Roche University CRNA 2025
.png)
